Phathom Pharmaceuticals (PHAT) Current Deferred Revenue (2023 - 2026)

Phathom Pharmaceuticals (PHAT) has 4 years of Current Deferred Revenue data on file, last reported at $33.0 million in Q1 2026.

• Current Deferred Revenue for Q1 2026 came in at $33.0 million, up 91.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $33.0 million (up 91.2% YoY), and the FY2025 annual result was $27.2 million, up 37.78% from the prior year.
• Current Deferred Revenue rose to $33.0 million in Q1 2026 per PHAT's latest filing, from $27.2 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $33.0 million in Q1 2026 and troughed at $276000.0 in Q2 2023.
• A 4-year average of $16.6 million and a median of $18.5 million in 2024 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2024 and 2025: Current Deferred Revenue jumped 3490.58% in 2024, then increased 4.79% in 2025.
• A 4-year view of Current Deferred Revenue shows it stood at $7.1 million in 2023, then jumped by 178.12% to $19.8 million in 2024, then surged by 37.78% to $27.2 million in 2025, then climbed by 21.16% to $33.0 million in 2026.
• Business Quant data shows PHAT's Current Deferred Revenue at $33.0 million in Q1 2026, $27.2 million in Q4 2025, and $24.3 million in Q3 2025.